Lightchain Capital

Recent News

aiProteins_Final_logo300
May 31, 2023

AI Proteins Announces the Formation of a Scientific Advisory Board Made up of Experts in Biotech and FDA Drug Approval

READ MORE
C4-logo-400
May 30, 2023

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC

READ MORE
SimpleRose-logo
May 22, 2023

St. Louis high-potential tech startup emerges from stealth mode

READ MORE
aiProteins_Final_logo300
May 18, 2023

AI Proteins Expands Leadership Team with Two Key Hires

READ MORE
wugen-logo-400
May 11, 2023

Wugen Announces Multiple Presentations at the European Hematology Association (EHA) 2023 Congress

READ MORE
wugen-logo-400
May 10, 2023

Wugen Appoints Industry Leader Mark Alles as Chair of the Board of Directors

READ MORE
C4-logo-400
May 04, 2023

C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

READ MORE
wugen-logo-400
April 19, 2023

Wugen Presents New Preclinical Data Reinforcing Anti-Tumor Functionality of WU-NK-101 at the American Association for Cancer Research (AACR) Annual Meeting 2023

READ MORE
C4-logo-400
April 19, 2023

C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

READ MORE

Contact Us

Lightchain Capital, LLC
PO Box 31729
St. Louis, MO 63131

 

LinkedIn

Submit

©2024 LIGHTCHAIN CAPITAL, LLC  All Rights Reserved | Privacy Policy
Website by Tidal Media Group